Furthermore, we show that DZNep treatment alone or in context of SARS‐CoV or SARS‐CoV‐2 infections reduces abundance of pulmonary fibrosis markers (e.g., SERPINE1, MMP14, and COL4A1) and increases levels of factors with antifibrotic activity (e.g., HOPX, PI3/ELAFIN, and SLPI; Fig 4D). The gene discussed is COL4A1; the disease is pulmonary fibrosis.